company background image
PROGEN logo

Prostatype Genomics OM:PROGEN Stock Report

Last Price

kr0.055

Market Cap

kr43.4m

7D

-11.6%

1Y

-88.5%

Updated

28 Mar, 2024

Data

Company Financials

Prostatype Genomics AB (publ)

OM:PROGEN Stock Report

Market Cap: kr43.4m

PROGEN Stock Overview

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests.

PROGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Prostatype Genomics AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prostatype Genomics
Historical stock prices
Current Share Pricekr0.055
52 Week Highkr1.95
52 Week Lowkr0.039
Beta0.35
1 Month Change1.85%
3 Month Change-42.11%
1 Year Change-88.49%
3 Year Change-99.57%
5 Year Changen/a
Change since IPO-99.21%

Recent News & Updates

Recent updates

Shareholder Returns

PROGENSE BiotechsSE Market
7D-11.6%1.4%1.9%
1Y-88.5%5.1%17.1%

Return vs Industry: PROGEN underperformed the Swedish Biotechs industry which returned 5.1% over the past year.

Return vs Market: PROGEN underperformed the Swedish Market which returned 17.1% over the past year.

Price Volatility

Is PROGEN's price volatile compared to industry and market?
PROGEN volatility
PROGEN Average Weekly Movement29.0%
Biotechs Industry Average Movement8.9%
Market Average Movement6.1%
10% most volatile stocks in SE Market12.9%
10% least volatile stocks in SE Market3.4%

Stable Share Price: PROGEN's share price has been volatile over the past 3 months.

Volatility Over Time: PROGEN's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20075Fredrik Perssonhttps://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company’s test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision.

Prostatype Genomics AB (publ) Fundamentals Summary

How do Prostatype Genomics's earnings and revenue compare to its market cap?
PROGEN fundamental statistics
Market capkr43.36m
Earnings (TTM)-kr41.43m
Revenue (TTM)kr3.73m

11.6x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PROGEN income statement (TTM)
Revenuekr3.73m
Cost of Revenuekr19.45m
Gross Profit-kr15.72m
Other Expenseskr25.72m
Earnings-kr41.43m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)-0.053
Gross Margin-421.62%
Net Profit Margin-1,111.45%
Debt/Equity Ratio0.3%

How did PROGEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.